Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

An older dog with newer tricks: Predicting efficacy of IFN-β treatment for multiple sclerosis.
Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs.
The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins.
Firategrast
Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis.
Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis.
The employment concerns of Americans with multiple sclerosis: Perspectives from a national sample.
Microglia in health and disease.
Keystone Symposium: Innate Immunity and Determinants of Microbial Pathogenesis - joint with - Mechanisms of Pro-Inflammatory Diseases
Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis
Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
GlaxoSmithKline Product Development Pipeline
Mechanism of action of mitoxantrone.
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
Extracellular Cues Influencing Oligodendrocyte Differentiation and (Re)myelination.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient.
ASNI Calgary 2015
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Free MED IQ Live CME Event on Multiple Sclerosis Nov 22nd
Episode 19 with Dr. Samuel Ludwin on treating MS subtypes
8th World Congress on Controversies in Neurology (CONy)
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.

Pages